Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, intra-patient dose-ascending subcutaneous MRA in rheumatoid arthritis
jRCT2080220688Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080220688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220688.